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ABSTRACT HIV-1 protease (HIVp) is an impor-
tant target for the development of therapies to treat
AIDS and is one of the classic examples of structure-
based drug design. The flap region of HIVp is known
to be highly flexible and undergoes a large conforma-
tional change upon binding a ligand. Accurately mod-
eling the inherent flexibility of the HIVp system is
critical for developing new methods for structure-
based drug design. We report several 3-ns molecular
dynamics simulations investigating the role of solva-
tion in HIVp flap rearrangement. Using an unligan-
ded crystal structure of HIVp, other groups have
observed flap reorganization on the nanosecond time-
scale. We have also observed rapid, initial flap move-
ment, but we propose that it may be caused by system
setup. The initial solvation of the system creates
vacuum regions around the protein that may encour-
age large conformational deformities. By reducing the
vacuum space created by the solvation routine, the
observed flap collapse is attenuated. Also, a more
thorough equilibration procedure preserves a more
stable protein conformation over the course of the
simulation. Proteins 2005;58:119–125.
© 2004 Wiley-Liss, Inc.
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INTRODUCTION
HIV-1 protease (HIVp) is one of the most extensively
studied enzymes, both experimentally and computation-
ally. HIVp is an aspartic protease with homology to the
mammalian aspartic proteases pepsin and renin. It is
active as a homodimer with a C2 axis of symmetry in the
unbound state and contains two Asp-Thr-Gly active-site
triads.1 HIVp cleaves the viral gag-pol polyprotein into
individual proteins and is required for proper assembly of
viral progeny. Inhibition of HIVp results in the production
of viral particles that are unable to infect other cells.2 Due
to its critical role in the viral life cycle, HIVp is an
attractive target for the development of AIDS therapies,3
and 7 drugs are currently marketed as HIVp inhibitors for
AIDS treatment. Unfortunately, resistance to these drugs
has developed rapidly.4 Thus, the design of HIVp inhibi-
tors with novel mechanisms of action and reduced resis-
tance liabilities is still desirable.
The catalytic residues of HIVp are located at the base of
a large open cavity, the ceiling of which is composed of 2
flaps— 1 from each monomer (Fig. 1). Upon ligand binding,
these flaps move 5–7 Å toward the base of the cavity,
closing in on the ligand, as is observed in all ligand-bound
crystal structures.5 In contrast to the bound structures,
the crystal structure of unbound HIVp has been solved
with the flaps in a semiopen conformation. Early molecu-
lar dynamics (MD) simulations proposed that the semi-
open flap structure found in the unliganded crystal struc-
tures was due to crystal packing effects, and that a closed
flap structure, like that of the bound structures, was likely
the predominant species found in solution.6,7 In contrast,
researchers who conducted a recent 10-ns MD simulation
of the unbound HIVp observed that a novel open-flap
conformation is achieved and maintained after approxi-
mately 3 ns.8 The structures were unique because no
open-flap structures have been observed experimentally,
although they are necessary to allow substrates to enter
the active site. Free energy calculations have been per-
formed on uncomplexed HIVp starting from the semiopen
flap conformation, moving to the closed-flap conformation,
as seen in ligand-bound structures.9 The computed free
energy of the flap transition predicts that the semiopen
flap conformation is approximately 7 kcal/mol more stable
than the closed-flap conformation without a bound ligand,
and that entropic freedom of the semiopen state in solution
is responsible for the free energy difference.
Several NMR studies have appeared that detail the
dynamics of the flap region.10,11 They propose that the
flaps are in rapid equilibrium among an ensemble of
semiopen conformations, which is in slow equilibrium with
open conformations (allowing the ligand access to the
active site) and closed-flap conformations. The NMR data
suggest that the tips of the flaps (residues 49–53) move
among this ensemble of semiopen states on the 1-ns
timescale. Both order parameters and chemical shift data
indicate that the flap bodies (residues 45–47) maintain a
-sheet conformation during the NMR experiments, sug-
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gesting less conformational flexibility on the subnanosec-
ond timescale.11
Our initial MD simulations of HIVp showed a dramatic
conformational change in the flap region after an equilibra-
tion time of only 120 ps (Fig. 1). The flaps collapsed
approximately 5 Å into the active site and remained
collapsed in the subsequent simulation. Such a large-scale
motion is not physically realistic on such a short timescale.
Since accurate simulations of the flap region of HIVp are
critical for structure-based drug design, we sought to
understand the observed flap collapse and its implication
for the conformational flexibility of the HIVp enzyme.
The solvation algorithm in AMBER612 superimposes
the solute in a pre-equilibrated box of TIP3P13 water. The
distance between the solute and solvent atoms is calcu-
lated and compared to the sum of the van der Waals radii.
If any solvent atom is closer than this distance, the entire
solvent molecule is removed. This creates a thin vacuum
layer around the solute (Fig. 2). For globular proteins, this
vacuum layer should pose few problems with the simula-
tion. The equilibration phase will adjust the water pack-
ing, and no adverse structural effects should be observed.
However, HIVp has a large active-site cavity that is
solvent-exposed on 2 sides and covered by 2 thin -strand
flaps. We propose that in our initial simulations, the flaps
of HIVp collapse to alleviate the initial vacuum layer and
that the protein collapse occurs before an appropriate
amount of water has a chance to enter the active-site
cavity.
To understand the importance of initial solvation, a
series of simulations were run to probe the role of solvation
in flap collapse. By changing the number of water mol-
ecules removed during the initial solvation, the flap col-
lapse is attenuated. Similarly, adding an additional pre-
equilibration of the water alone (protein held fixed) also
prevents the initial flap collapse and provides a stable
protein conformation over the course of the simulation. It
should be noted that pre-equilibration of solvent is stan-
dard practice in modern MD simulations; however, to our
knowledge, there have been no reports of the consequences
of inappropriate solvation on large, open active-site cavi-
ties.
COMPUTATIONAL METHODS
The coordinates for the unliganded monomer of HIVp
were obtained from the Protein Data Bank14 (PDB acces-
sion code: 1HHP1) and the homodimer was generated via
symmetry operations. Hydrogens were added with the
program MOE.15 The hydrogens were minimized using the
AMBER94 force field16 as implemented in MOE. The side
chains were allowed to relax by minimizing iteratively in
stages out from the active site. The minimization protocol
consisted of steepest descent steps to a root-mean-square
(RMS) gradient of 10 kcal/mol  Å, conjugate gradient steps
to a gradient of 1 kcal/mol  Å, and 200 truncated-Newton
steps or a convergence of 0.001 kcal/mol  Å. The 4e
charge of HIVp was neutralized by the inclusion of 4
chloride counterions. The electrostatics module in MOE
was used to calculate the potential and place the counter
ions iteratively 10Å from the protein surface in the most
electropositive regions.
Several different methods of solvation were used in
setup. The initial studies used the default solvation algo-
rithm implemented in the LEAP module of the AMBER612
suite of programs to generate a 62  62  82 Å3 box of
TIP3P13 water. In the solvation algorithm, the closeness
parameter controls the minimum distance between the
Fig. 1. (A) 1HHP crystal structure of HIVp. The catalytic aspartates
from each monomer are shown in ball-and-stick configuration. The flap
region (residues 45–56 from each monomer) is shown in green and the
flap tips (residues 49–53) in yellow. Structures are aligned by C. (B)
Initial flap collapse after 120-ps equilibration. The 1HHP structure is
shown in red, and the collapsed structure in cyan.
Fig. 2. Cartoon of protein superposition into a solvent box, showing
the creation of a small vacuum layer. In the LEAP module of AMBER6, the
closeness parameter controls how close the solvent is allowed to the
protein.
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solvent molecules and the protein. To determine close
contacts, the sum of the van der Waals radii for 2 atoms is
multiplied by the closeness parameter (C) and compared to
the distance between the atoms. Thus, by decreasing the
magnitude of the closeness parameter, more solvent mol-
ecules are retained closer to the protein surface. Changing
this parameter does not affect the density of the bulk of the
water box, only the number of solvent molecules that are
removed at the protein surface. Three additional systems
were created using different values of C: 1.0, 0.5, and 0.25.
To vary the initial number of waters placed in the active-
site cavity, a cap of solvent with the desired closeness was
centered on the flap region. We performed 10,000 steps of
minimization of the water and protein hydrogens using
sander_classic. The resulting structure was placed in a
standard TIP3P water box of 62  62  82 Å3, and
counterions were reintroduced to ensure a net-neutral
simulation. This system was minimized an additional
10,000 steps with the protein heavy atoms fixed (first 10
steps of steepest descent for coarse corrections and then
9990 steps of conjugate gradient minimization).
A fourth simulation of 1HHP used the standard water
setup (C  1); however, the protein was held fixed during
the initial warming to 298 K (50 ps) and equilibration (200
ps) to allow the water to optimally complement the sur-
faces and cavities of the frozen protein structure. A second
warming and equilibration (as described below) was then
performed with no restraints.
MD simulations were performed with the AMBER94
force field16 and the sander_classic module in the AM-
BER612 suite of programs. For all simulations, the tempera-
ture was raised to 298 K over 50 ps in 10-ps intervals,
followed by an equilibration phase of 200 ps. The simula-
tion was run in the NPT ensemble, and SHAKE17 was
used to restrain hydrogen bonds lengths. A 2-fs timestep
was used, along with a 10-Å cutoff for nonbonded interac-
tions. The nonbonded pair list was updated every 15 steps
and particle mesh Ewald18 (PME) was used for long-range
electrostatics. The production phase of the MD simula-
tions was 3 ns for the 4 different solvation routines.
Root-mean-square deviation (RMSD) traces were calcu-
lated using the carnal module of the AMBER6 suite of
programs based on the C positions of the 1HHP crystal
structure. Order parameters were calculated from the MD
trajectory using the ptraj module of the AMBER suite to
calculate the autocorrelation function for each N-H inter-
nuclear vector. The resulting correlation curves were fit to
the Lipari–Szabo “model-free” equation.19 C RMS fluctua-
tions were also calculated for the 3-ns trajectory using
ptraj.
Cavity waters were quantized by defining a sphere to
represent the active-site volume for each model. A reason-
able and consistent means of evaluating cavity size was
needed that was independent of the large conformational
changes observed. The center of the cavity was determined
by averaging the C positions of residues that lined the
active site (23–32, 47–54, 84, 23–32, 47–54, 84). The
radius of the spherical cavity was the average of the
distances from the center to the C positions of the
selected residues. As the protein structure relaxed during
the simulations, the center and radii changed according to
the amount of conformational change. Waters inside this
sphere were considered cavity water.
RESULTS AND DISCUSSION
Agreement With NMR Data
Using a properly equilibrated system, we see good
agreement with recent experimental data. The simulation
with the pre-equilibrated water shows motion that is
consistent with the NMR data,10,11 indicating that the
HIVp flaps are sampling an ensemble of states around the
semiopen crystal conformation. To compare our simulation
with existing NMR data, we calculated both order parame-
ters for the internuclear N-H vector and C atomic fluctua-
tions over 3 ns of our trajectory. Comparing calculated and
experimental order parameters can be problematic; how-
ever, qualitative trends are generally consistent.20 The
calculated order parameters and RMSD fluctuations for
each monomer are summarized in Figure 3. Freedberg et
al.11 found that only residues 37–41 (flap elbows), 49–53
(flap tips), and 80 of HIVp have order parameters  0.75.
Our calculated values follow this same trend of low-order
parameters only in these same regions. The residues
Fig. 3. (A) Calculated order parameters (S2) for the N-H internuclear
vector over 3 ns of the pre-equilibrated trajectory. (B) C RMSD
fluctuations in angstrom units. The two monomers are shown together:
residues 2–99 in black and 2–99 in gray.
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43–48 (flap bodies) have high order parameters and low
RMSD fluctuations, which again agree with the NMR
results that these residues maintain a -sheet conforma-
tion on the timescale investigated. There are small differ-
ences between the 2 monomers, illustrating the limita-
tions of a comparing a single MD trajectory to the averaging
obtained in an NMR experiment. The agreement between
the calculated and experimental order parameters indi-
cates that our pre-equilibrated simulation is sampling
appropriate conformations on the nanosecond timescale.
For the simulation with pre-equilibrated water, we do
not see the dramatic flap reorganization reported by Scott
and Schiffer.8 They point out that there are important
crystal contacts in the 1HHP structure, and it is very
possible that these interactions stabilize the semiopen
form of HIVp. They make the intriguing argument that
without these contacts in the MD simulation, the semi-
open form is no longer stable. An unstable protein conforma-
tion should change over the course of an MD simulation, and
they hypothesize that this is the cause of the large flap
rearrangement seen within 3 ns of their simulation.
However, our simulations also lack those crystal con-
tacts, yet the protein conformation remains stable. The
exact cause for the differences in our simulation results is
unclear. First and foremost, their simulations were done
with another excellent MD software package, GROMOS.21
Differences are inherent when using another code and
force field. The AMBER94 force field has a very slight
tendency to favor -helices over extended sheets,22–24 so
one might expect that our simulations would be biased
toward a folding of the -sheet flaps. Since we did not see
this with pre-equilibrated water, we feel this is strong
support for the stability of the semiopen form seen in the
crystal structure. New work by McCammon and coworkers
has recently appeared, examining the conformational behav-
ior of wild-type and mutant forms of HIVp.25 They started
with closed forms of the protein, removed the ligands, and
ran 22-ns MD simulations using AMBER. In that length of
time, both the wild-type and mutant HIVp sampled closed
and semiopen forms with large degrees of flexibility seen in
the flap tips, but opening of the flaps was not observed.
It is possible that the flap rearrangement seen by Scott
and Schiffer8 may be due to the issue of solvating the
cavity. We observe large conformational changes in the
flaps with under- or oversolvation of the binding-site
cavity (see below). Their paper states that they initiated
their MD simulations at 300 K, with harmonic constraints
on the protein atoms, and removed those constraints after
only 10 ps. This short time would not have allowed much
water to enter or escape the binding site if needed, if
pre-equilibration was not performed. We are not implying
that Scott and Schiffer’s simulation was flawed. It is very
common for setup to include pre-equilibration of the water
but not be explicitly reported in the paper. Furthermore,
we show below that a tighter packing of initial waters
provides a stable simulation (C  0.5). If the initial
solvation protocol in GROMOS places more waters in the
cavity, the influence of vacuum around the protein would
obviously be reduced.
Comparing Initial Solvation Conditions
Simulations using 4 different solvation setups were
examined over the course of 3 ns of simulation. Three
simulations were run varying the “closeness” parameter
(C) in the solvation routine in AMBER6 (see Methods
section) and a fourth simulation used an additional, initial
pre-equilibration phase, where the protein was held fixed
and the solvent was allowed to relax around it (not
performed in the C  1.0, C  0.5, and C  0.25
simulations). The RMSD traces for the simulations are
shown in Figure 4, and the potential energy traces are
provided as Supplementary Information. All 4 simulations
exhibit proper equilibration and stable potential energy
traces over the course of the 3-ns simulation.
The RMSD from the crystal structure C positions
stabilizes at 1.5 Å for the pre-equilibrated water simula-
tion. The RMSD traces for the simulations with different
closeness parameters show more variation. The RMSD
trace for the C  0.5 simulation most closely resembles the
pre-equilibrated water trace. In contrast, the C  0.25
simulation shows a constant trend away from the crystal
position. It is interesting to observe that RMSD trace for
the C  1 simulation (default solvation) initially diverges
but at approximately 2 ns returns to a structure similar to
the starting conformation.
The number of water molecules present in the active-site
cavity can be quantified and compared among the 4
simulations (Tables I and II). As expected, the initial
amount of water in the cavity varies with C and directly
reflects the amount of vacuum created around the binding
site. There is a significant difference between the C  1.0
and the C  0.25 simulations, with 33 and 137 water
Fig. 4. RMSD traces for the 4 simulations: black is pre-equilibrated
water, green is C  0.25, blue is C  0.5, and red is C  1.0.
TABLE I. Number of Water Molecules in the HIVp





Number of Cavity Waters
After 200-ps Equilibration
C  1.0 33 49
C  0.50 79 80
C  0.25 137 130
122 K.L. MEAGHER AND H.A. CARLSON
molecules in the respective cavities. After 200 ps of all-
atom equilibration, the amount of water in the active-site
cavity is approximately the same as the initial solvation
(Table I); however, in the C  1.0 and C  0.25 simula-
tions, the protein has deformed significantly (Fig. 5). For
C  1.0, slightly more water is seen entering the cavity.
The large flap motion seen in the C  0.25 and C  1.0
simulations indicates that protein deformation occurs be-
fore bulk water has a chance to enter or leave the cavity.
Table II demonstrates the importance of pre-equilibrat-
ing the water while holding the protein fixed. The initial
solvation places 27 waters in the active site. After pre-
equilibration in which the protein is held frozen, there are
85 waters in the cavity! A difference of 58 TIP3P water
molecules is a little more than 1700 Å3.13 It should be
noted that the protein was held fixed, so identical spheres
were used to determine the number of waters. The in-
crease observed is not from any deformation of the protein,
but comes from diffusion of water molecules into an
undersolvated cavity. After an additional 200 ps of equili-
bration, where the protein has also been allowed to relax,
89 waters are observed in the cavity.
Since the number of cavity waters changed only slightly
after the second equilibration, pre-equilibrating the water
appears to create stable and appropriate solvation of the
active-site cavity. Comparing the three C-dependent simu-
lations with the pre-equilibrated simulation shows that
the C  0.5 case provides the most similar initial solvation,
placing 79 waters in the active-site cavity, and, after
all-atom equilibration, 80 waters remain in the cavity. It is
interesting that similar numbers of water molecules in the
C  0.5 case also show a stable simulation similar to the
pre-equilibrated case.
Examining snapshots taken along the MD trajectory for
all 4 systems illustrates the conformational consequences
of the different solvation models (Fig. 5). The C  1.0
system shows significant collapse of the flap region after
200 ps of equilibration. However, the pre-equilibrated
water system and the C  0.5 system do not exhibit this
collapse and instead maintain the crystal structure confor-
mation (Fig. 5). It is interesting that the flaps appear to be
opening in the C  0.25 simulation, perhaps due to too
many water molecules in the active-site cavity. Over the
course of the 3-ns simulation, the pre-equilibrated and C 
0.5 systems retain their crystal structure conformation, as
can be seen in the stable RMSD traces of Figure 4 and the
snapshots from the simulations shown in Figure 5.
These observations are consistent with our hypothesis
regarding the influence of solvation on conformation.
Allowing the water to pack extremely close to the protein
(C  0.25) results in a diverging RMSD trace due to large
motions as the flaps move to accommodate the extra water.
The protein structure has changed rapidly and dramati-
cally, indicating that the C  0.25 simulation does not
represent realistic solvation of the HIVp active site. Con-
versely, using the default parameter (C  1.0) initially
results in inadequate solvation of the active-site cavity and
flap collapse. However, extending the simulation to 2 ns,
the C  1.0 simulation samples conformations more
closely related to the semiopen flap structure seen in the
crystal structure. This is consistent with the previous free
energy calculation,9 indicating that the semiopen flap
structures are more favorable than closed flaps for unligan-
ded HIVp. The most appropriate solvation is observed in
the C  0.5 and pre-equilibrated systems. These systems
show appropriate, stable dynamics—sampling an en-
semble of semiopen conformations. Certainly, pre-equilibra-
tion of the water is most appropriate and leads to the most
realistic simulations. This is why it is the current standard
in MD simulations; however, we have demonstrated the
potential conformational consequences of inappropriate sol-
vation—both over- and undersolvation—of a large cavity.
By investigating the effect of the closeness parameter,
we have found that flap motion is dependent on the
solvation of the active-site cavity, particularly in the early
phases of the simulation. By manipulating the number of
waters retained in the active site, we observe a range of
flap conformations.
CONCLUSIONS
Using a properly equilibrated system, we see good
agreement with recent NMR experiments. This indicates
that our system is sampling appropriate conformations on
the nanosecond timescale. We are not able to reproduce
the large rearrangements seen by Scott and Schiffer.8 It is
possible that this disagreement is the result of our chosen
software package and force field, but it may be related to
the solvation of the binding site.
Appropriate solvation of proteins with large cavities is
critical for reasonable conformational behavior in MD
simulations. For HIVp, the layer of vacuum created with
the standard solvation routine can cause the flaps to
collapse into the active-site cavity, leading to a less natural
trajectory. By decreasing the cutoff distance between
solvent molecules and the solute, solvent is allowed to pack
closer to the protein surface, lessening the effects of the
vacuum layer. Using a series of simulations, we have
shown that including either too much (C  0.25) or not
enough (C  1.0) water in the HIVp active-site cavity leads
to unrealistic protein conformations early in the simula-
tion. Using an intermediate value (C  0.5), or holding the
protein fixed and equilibrating the water around the
protein structure, provides appropriate solvation and pro-
duces a stable trajectory. [Supporting material including
the potential energy traces for the four simulations is
available.]
TABLE II. Number of Water Molecules in the HIVp Active-
Site Cavity After the Initial Solvation, Pre-Equilibration of

















Pre-equilibrated 27 85 89
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